CCRK Polyclonal Antibody
$250.00 – $350.00
Conditions of optimal CCRK polyclonal antibody performance should be determined experimentally by the investigator.
- Product Details
- Description
- Additional information
- More Offers
| Catalog No. | PA001053-C11329 |
|---|---|
| Product Name | CCRK Polyclonal Antibody |
| Supplier Name | Syd Labs, Inc. |
| Brand Name | Syd Labs |
| Synonyms | Cell cycle-related kinase, EC 2.7.11.22, Cyclin-kinase-activating kinase p42, CDK-activating kinase p42, CAK-kinase p42 |
| Specificity/Sensitivity | CCRK antibody detects endogenous levels of total CCRK protein. |
| Reactivity | Human, Mouse, Rat. |
| Immunogen | The antiserum was produced against synthesized peptide derived from internal of human CCRK. |
| Purification | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Form Of Antibody | Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02% sodium azide and 50% glycerol. |
| Stability & Storage | Stable for 1 year at -20°C and 3 months at 4°C. For maximum recovery of the product, centrifuge the original vial after thawing and before removing the cap. Aliquot to avoid repeated freezing and thawing. |
| Note | Conditions of optimal CCRK antibody performance should be determined experimentally by the investigator. |
| Order Offline | Syd Labs, Inc. 4 Avenue E, Hopkinton, MA 01748 USA. Phone: 1-617-401-8149 Fax: 1-617-606-5019 Email: message@sydlabs.com |
Description
PA001053-C11329: CCRK Polyclonal Antibody
Introduction
Cell cycle-related kinase (CCRK) is a newly identified protein kinase homologous to Cdk7. We have previously shown that CCRK is a candidate oncogene in human glioblastoma. However, whether CCRK is a bona fide oncogene remains to be tested. The aim of this study was to investigate the role of CCRK in human colorectal cancer carcinogenesis. By Western blotting, we analysed the expression profile of CCRK protein in 10 colorectal cancer tissue samples and their adjacent normal colon tissues and in seven colorectal cancer cell lines. CCRK protein expression was also investigated by immunohistochemistry in a colorectal tissue microarray, which contained 120 cases of primary colorectal cancer and adjacent normal colorectal mucosa. The effects of CCRK knock-down on cell cycle profile and proliferation of colorectal cancer cells were examined by transfecting LoVo and DLD1 human colorectal cancer cell lines by either short-hairpin RNA (shCCRK) or small interfering RNA targeting CCRK (siCCRK). We found that CCRK protein levels were elevated by more than 1.5-fold in 70% of colorectal cancer patient samples examined and CCRK was detectable in all seven colorectal cancer cell lines tested. Colorectal tissue microarray indicated that overexpression of CCRK was detected in 62/109 (56.9%) of informative colorectal cancer cases and was significantly associated with the tumour pT and pN status (p<0.05). Suppression of CCRK by siCCRK led to G1 phase cell cycle arrest and reduced cell growth. Consistently, stable clones of LoVo and DLD1 cells expressing shCCRK exhibited decreased cell proliferation rates. Furthermore, we showed that CCRK is required for the phosphorylation of Cdk2 (on Thr-160) and Rb (on Ser-795) and the expression of cyclin E.
Other CCRK Antibody:
CCRK Polyclonal Antibody
Additional information
| Ship from Country | USA |
|---|---|
| Size | 100 ug, 50 ug |
